US-based medical device firm MC3 Cardiopulmonary has completed the acquisition of surgical cannula product assets from Terumo Cardiovascular.
Under the deal, MC3 acquired Terumo’s previously marketed Surgical Cannula line, which includes brands such as Sarns Soft-Flow arterial cannula.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe Terumo surgical cannula line, which is claimed to be one of the largest cardiac surgery cannula lines worldwide, includes 200 product stock keeping units (SKUs).
The company noted the Soft-Flow arterial cannula is the world’s first dispersion tip aortic cannula designed for clinical users.
MC3 developed a 60,000ft² manufacturing facility on its ten acre campus in Dexter, Michigan, to support production of Soft-Flow arterial cannula, which is expected during the first half of next year.
The acquisition is part of the company’s aim to transform into a global cardiopulmonary medical device manufacturer.
MC3 Cardiopulmonary CEO Scott Merz said: "This is a significant milestone for us, and we are excited to return the legacy of Soft-Flow arterial cannula to the users and patients it will serve.
"In order to support our goals as a global medical device company, we have built a world-class facility just outside of Ann Arbor in Dexter, Michigan.
"The location provides close proximity to the University of Michigan, Detroit International Airport and skilled knowhow within our sector."
Established in 1991 as a spinout of the University of Michigan (UMich), MC3 develops medical devices to meet acute and chronic cardiopulmonary clinical needs.
The company was founded with the aim of commercialising intellectual property related to artificial heart and lung technologies from UMich.
The company is currently focused on becoming a leading medical device developer and manufacturer in the cardiopulmonary device community. It has expertise in patient physiology, hemodynamics, technology and caregiver needs.
Image: MC3’s new manufacturing facility at Dexter. Photo: courtesy of MC3 Cardiopulmonary.
